At the same time, this effect was not observed in an AR-negative (AR-) SCC-25 cell line, which suggested that nAR promotes the EGFR signaling pathway in head and neck tumors, therefore making it a perfect target for targeted therapy in this tumor type [67]. Here, CPSF4 is linked to neoplasm.